Selected research
Market Structure
Global Breviscapine for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Breviscapine for Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Breviscapine for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Breviscapine for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Breviscapine for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Breviscapine for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Breviscapine for Injection include YUNNAN BIOVALLEY PHARMACEUTICAL, Tasly Pharmaceutical Group, Sihuan Pharmaceutical, CSPC Pharmaceutical Group, China Shineway Pharmaceutical, Kunming Longjin Pharmaceutical, KPC Pharmaceuticals, Jilin Longtai Pharmaceutical and Hunan Hengsheng Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Breviscapine for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Breviscapine for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Breviscapine for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Breviscapine for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.
Breviscapine for Injection Segment by Company
YUNNAN BIOVALLEY PHARMACEUTICAL
Tasly Pharmaceutical Group
Sihuan Pharmaceutical
CSPC Pharmaceutical Group
China Shineway Pharmaceutical
Kunming Longjin Pharmaceutical
KPC Pharmaceuticals
Jilin Longtai Pharmaceutical
Hunan Hengsheng Pharmaceutical
Breviscapine for Injection Segment by Type
Freeze-Dried Powder
Aqueous Solution
Breviscapine for Injection Segment by Application
Hospital
Clinic
Other
Breviscapine for Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Breviscapine for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Breviscapine for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Breviscapine for Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Breviscapine for Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Breviscapine for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Breviscapine for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Breviscapine for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Freeze-Dried Powder
- Aqueous Solution
Applications
- Hospital
- Clinic
- Other
Companies covered
- YUNNAN BIOVALLEY PHARMACEUTICAL
- Tasly Pharmaceutical Group
- Sihuan Pharmaceutical
- CSPC Pharmaceutical Group
- China Shineway Pharmaceutical
- Kunming Longjin Pharmaceutical
- KPC Pharmaceuticals
- Jilin Longtai Pharmaceutical
- Hunan Hengsheng Pharmaceutical
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Breviscapine for Injection Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Breviscapine for Injection Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Breviscapine for Injection Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Breviscapine for Injection Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Breviscapine for Injection Market Dynamics
- 2.1 Breviscapine for Injection Industry Trends
- 2.2 Breviscapine for Injection Industry Drivers
- 2.3 Breviscapine for Injection Industry Opportunities and Challenges
- 2.4 Breviscapine for Injection Industry Restraints
3 Breviscapine for Injection Market by Manufacturers
- 3.1 Global Breviscapine for Injection Revenue by Manufacturers (2021-2026)
- 3.2 Global Breviscapine for Injection Sales by Manufacturers (2021-2026)
- 3.3 Global Breviscapine for Injection Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Breviscapine for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Breviscapine for Injection Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Breviscapine for Injection Manufacturers, Product Type & Application
- 3.7 Global Breviscapine for Injection Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Breviscapine for Injection Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Breviscapine for Injection Players Market Share by Revenue in 2025
- 3.8.3 2025 Breviscapine for Injection Tier 1, Tier 2, and Tier 3
4 Breviscapine for Injection Market by Type
- 4.1 Breviscapine for Injection Type Introduction
- 4.1.1 Freeze-Dried Powder
- 4.1.2 Aqueous Solution
- 4.2 Global Breviscapine for Injection Sales by Type
- 4.2.1 Global Breviscapine for Injection Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Breviscapine for Injection Sales by Type (2021-2032)
- 4.2.3 Global Breviscapine for Injection Sales Market Share by Type (2021-2032)
- 4.3 Global Breviscapine for Injection Revenue by Type
- 4.3.1 Global Breviscapine for Injection Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Breviscapine for Injection Revenue by Type (2021-2032)
- 4.3.3 Global Breviscapine for Injection Revenue Market Share by Type (2021-2032)
5 Breviscapine for Injection Market by Application
- 5.1 Breviscapine for Injection Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Breviscapine for Injection Sales by Application
- 5.2.1 Global Breviscapine for Injection Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Breviscapine for Injection Sales by Application (2021-2032)
- 5.2.3 Global Breviscapine for Injection Sales Market Share by Application (2021-2032)
- 5.3 Global Breviscapine for Injection Revenue by Application
- 5.3.1 Global Breviscapine for Injection Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Breviscapine for Injection Revenue by Application (2021-2032)
- 5.3.3 Global Breviscapine for Injection Revenue Market Share by Application (2021-2032)
6 Global Breviscapine for Injection Sales by Region
- 6.1 Global Breviscapine for Injection Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Breviscapine for Injection Sales by Region (2021-2032)
- 6.2.1 Global Breviscapine for Injection Sales by Region (2021-2026)
- 6.2.2 Global Breviscapine for Injection Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Breviscapine for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Breviscapine for Injection Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Breviscapine for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Breviscapine for Injection Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Breviscapine for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Breviscapine for Injection Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Breviscapine for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Breviscapine for Injection Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Breviscapine for Injection Revenue by Region
- 7.1 Global Breviscapine for Injection Revenue by Region
- 7.1.1 Global Breviscapine for Injection Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Breviscapine for Injection Revenue by Region (2021-2026)
- 7.1.3 Global Breviscapine for Injection Revenue by Region (2027-2032)
- 7.1.4 Global Breviscapine for Injection Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Breviscapine for Injection Revenue (2021-2032)
- 7.2.2 North America Breviscapine for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Breviscapine for Injection Revenue (2021-2032)
- 7.3.2 Europe Breviscapine for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Breviscapine for Injection Revenue (2021-2032)
- 7.4.2 Asia-Pacific Breviscapine for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Breviscapine for Injection Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Breviscapine for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 YUNNAN BIOVALLEY PHARMACEUTICAL
- 8.1.1 YUNNAN BIOVALLEY PHARMACEUTICAL Company Information
- 8.1.2 YUNNAN BIOVALLEY PHARMACEUTICAL Business Overview
- 8.1.3 YUNNAN BIOVALLEY PHARMACEUTICAL Breviscapine for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 YUNNAN BIOVALLEY PHARMACEUTICAL Breviscapine for Injection Product Portfolio
- 8.1.5 YUNNAN BIOVALLEY PHARMACEUTICAL Recent Developments
- 8.2 Tasly Pharmaceutical Group
- 8.2.1 Tasly Pharmaceutical Group Company Information
- 8.2.2 Tasly Pharmaceutical Group Business Overview
- 8.2.3 Tasly Pharmaceutical Group Breviscapine for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Tasly Pharmaceutical Group Breviscapine for Injection Product Portfolio
- 8.2.5 Tasly Pharmaceutical Group Recent Developments
- 8.3 Sihuan Pharmaceutical
- 8.3.1 Sihuan Pharmaceutical Company Information
- 8.3.2 Sihuan Pharmaceutical Business Overview
- 8.3.3 Sihuan Pharmaceutical Breviscapine for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sihuan Pharmaceutical Breviscapine for Injection Product Portfolio
- 8.3.5 Sihuan Pharmaceutical Recent Developments
- 8.4 CSPC Pharmaceutical Group
- 8.4.1 CSPC Pharmaceutical Group Company Information
- 8.4.2 CSPC Pharmaceutical Group Business Overview
- 8.4.3 CSPC Pharmaceutical Group Breviscapine for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 CSPC Pharmaceutical Group Breviscapine for Injection Product Portfolio
- 8.4.5 CSPC Pharmaceutical Group Recent Developments
- 8.5 China Shineway Pharmaceutical
- 8.5.1 China Shineway Pharmaceutical Company Information
- 8.5.2 China Shineway Pharmaceutical Business Overview
- 8.5.3 China Shineway Pharmaceutical Breviscapine for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 China Shineway Pharmaceutical Breviscapine for Injection Product Portfolio
- 8.5.5 China Shineway Pharmaceutical Recent Developments
- 8.6 Kunming Longjin Pharmaceutical
- 8.6.1 Kunming Longjin Pharmaceutical Company Information
- 8.6.2 Kunming Longjin Pharmaceutical Business Overview
- 8.6.3 Kunming Longjin Pharmaceutical Breviscapine for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Kunming Longjin Pharmaceutical Breviscapine for Injection Product Portfolio
- 8.6.5 Kunming Longjin Pharmaceutical Recent Developments
- 8.7 KPC Pharmaceuticals
- 8.7.1 KPC Pharmaceuticals Company Information
- 8.7.2 KPC Pharmaceuticals Business Overview
- 8.7.3 KPC Pharmaceuticals Breviscapine for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 KPC Pharmaceuticals Breviscapine for Injection Product Portfolio
- 8.7.5 KPC Pharmaceuticals Recent Developments
- 8.8 Jilin Longtai Pharmaceutical
- 8.8.1 Jilin Longtai Pharmaceutical Company Information
- 8.8.2 Jilin Longtai Pharmaceutical Business Overview
- 8.8.3 Jilin Longtai Pharmaceutical Breviscapine for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Jilin Longtai Pharmaceutical Breviscapine for Injection Product Portfolio
- 8.8.5 Jilin Longtai Pharmaceutical Recent Developments
- 8.9 Hunan Hengsheng Pharmaceutical
- 8.9.1 Hunan Hengsheng Pharmaceutical Company Information
- 8.9.2 Hunan Hengsheng Pharmaceutical Business Overview
- 8.9.3 Hunan Hengsheng Pharmaceutical Breviscapine for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Hunan Hengsheng Pharmaceutical Breviscapine for Injection Product Portfolio
- 8.9.5 Hunan Hengsheng Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Breviscapine for Injection Value Chain Analysis
- 9.1.1 Breviscapine for Injection Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Breviscapine for Injection Production Mode & Process
- 9.2 Breviscapine for Injection Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Breviscapine for Injection Distributors
- 9.2.3 Breviscapine for Injection Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst